### PCT

## WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (51) International Patent Classification 6: (11) International Publication Number: WO 97/29369 G01N 33/49, B01D 39/20 A1 (43) International Publication Date: 14 August 1997 (14.08.97) (21) International Application Number: PCT/NL97/00046 (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, (22) International Filing Date: HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, 10 February 1997 (10.02.97) LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (KE, LS, MW, SD, SZ, UG). Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, (30) Priority Data: 1002296 9 February 1996 (09.02.96) NL TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (71) Applicant (for all designated States except US): MICRO DIAG-(BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, NOSTIC INNOVATIONS NEDERLAND B.V. [NL/NL]; Burgemeester Martenssingel 60, NL-2806 CW Gouda (NL). (72) Inventor; and **Published** (75) Inventor/Applicant (for US only): DE ROOIJ, Felix, Wilhel-With international search report. mus, Marie [NL/NL]; Burgemeester Martenssingel 60, NL-In English translation (filed in Dutch). 2806 CW Gouda (NL). (74) Agent: DE BRUIJN, Leendert, C.; Nederlandsch Octrooibu-

(54) Title: METHOD AND KIT FOR SEPARATING PLASMA FROM WHOLE BLOOD

reau, Scheveningseweg 82, P.O. Box 29720, NL-2502 LS

#### (57) Abstract

The Hague (NL).

The invention relates to a method for separating plasma from whole blood, in which: a) a mixture of whole blood, a blood anticoagulant and a diluent is prepared in a container provided with a sealing cap, and b) the mixture obtained under a) is passed through a filter containing glass fibres. Preferably, step a) is carried out in a hypodermic syringe in which a pressure prevails which is lower than the pressure prevailing at ambient temperatures. The invention also relates to a kit for separating plasma from whole blood, the kit comprising at least a container which contains a diluent, and a filter containing glass fibres.

#### Method and kit for separating plasma from whole blood

The invention relates to a method for separating plasma from whole blood, in which:

- a) a mixture of whole blood, a blood anticoagulant and a diluent is prepared in a container provided with a sealing cap, and
- b) the mixture obtained under a) is passed through a filter containing glass fibres.

Belgian Patent Application 849,898 describes a device for diluting and filtering a sample having a very small volume, such as, for 10 example, a blood sample. Said device comprises a container which is made of a flexible plastic material and which contains a liquid diluent for the sample to be treated. The container is furthermore provided with a hollow cylindrical neck whose extremity is sealed with a removable stopper, and a cylindrical tube made of a flexible plastic material. 15 internal diameter of the cylindrical tube is essentially equal to the external diameter of the neck. The extremity of the cylindrical tube is inserted into a nozzle or fixed on a filter, the nozzle being sealed by a cannula. The container may optionally contain a capillary which contains a measured quantity of the sample, for example a blood sample. To dilute and filter, for example, a blood sample, the procedure is as follows. First the stopper is removed and the blood sample is transferred to the container either by means of the capillary or directly with the aid of an hypodermic syringe. The cylindrical tube is then mounted on the neck of the container and the device is shaken in such a way that a homogeneous 25 mixture of the blood sample and the diluent is obtained, care being taken to ensure that the filter is not moistened. The homogeneous mixture is then filtered by squeezing the container, in which process the homogeneous mixture passes through the filter and a filtrate is obtained which has the desired dilution. A disadvantage of said device is that it 30 is unsuitable for separating plasma from quantities of whole blood of. for example, less than 100  $\mu l$  because the yield of pure plasma is low when such a small quantity of whole blood is separated. A further disadvantage of the device according to Belgian Patent Application 848,898 is that a large dilution has to be used in order to obtain an adequate volume of the homogeneous mixture: the volumetric ratio of the diluent and the blood sample should be between 10:1 and 1000:1. After dilution and filtering, therefore, a very dilute plasma will be obtained, as a result of which only diagnostic tests having a low sensitivity can

. 15

30

be carried out.

In medical diagnostics, the separation of plasma from whole blood is extremely important for analysing constituents present in the blood. Such analyses often take place with the aid of rapid diagnostic 5 means. Rapid diagnostic means are, for example, substrates which comprise a separating matrix for separating plasma from whole blood and a test reagent. In this procedure, a drop of whole blood is applied to the substrate, clear plasma passing through the separating matrix and the blood corpuscles, such as erythrocytes and leucocytes, remaining behind 10 in the matrix. The plasma then reacts with the test reagent, in which process a colour change occurs which is then evaluated visually or spectrophotometrically. A disadvantage of said rapid diagnostic means is that haemolysis of erythrocytes may occur, in which process haemoglobin is entrained with the plasma and may interfere with the colour reaction.

These problems do not occur, for example, in the case of rapid diagnostic means in which plasma containing no haemolysis products is applied instead of whole blood. In this case, the plasma first has to be separated from the whole blood by means of centrifuging, after which the plasma can be separated from the blood corpuscles deposited by means of 20 pipetting. The separation of plasma from whole blood by this method is not easy if it has to be carried out on a small scale. This is primarily of importance in the case of, for example, children, where the taking of a small amount of blood by means of a heel or finger prick results in far fewer problems with the patients than if blood is collected with the small vacuum tubes normally used. A small vacuum tube is a small tube which has a capacity of approximately 7 to 10 ml. which is provided with a stopper made, for example, of rubber and which has to be fitted on an injection needle after the injection needle has been introduced into a vein, for example a vein in the arm (venepuncture). Because a lower pressure prevails in the small vacuum tube than in the vein, blood will flow out of the vein into the small vacuum tube.

Another disadvantage of the method described above is that the separation of the plasma has to be carried out by expert staff or by staff specially trained for the purpose and that special equipment is 35 required. It is therefore not possible to collect whole blood and to separate the plasma therefrom at the same operational site. This is of importance, for example, under circumstances in which urgent help has to be offered and one or more diagnostic tests have to be carried out and special equipment is not available. Thus, for example, a general

practitioner or a medical specialist will possibly consider it necessary, when visiting patients at home or in cases where acute help is needed, respectively, to carry out a certain test but will not be in a position to extract the required amount of plasma rapidly and expediently.

5 Another example is the evaluation of new diagnostic blood parameters for which no specific whole blood tests are generally available for a long time. Only small amounts of blood are also necessary for many diagnostic tests, for example tests for the determination of the concentration of a metabolite, a hormone or an antibody. Furthermore, for example, veterinary surgeons cannot obtain an amount of plasma for a certain diagnostic test from an animal in its own living environment, for example a cow in its shed.

US Patent Specification 4,477.575 describes a method for separating plasma from whole blood in which whole blood is applied to a layer of glass fibres. A device is also described for separating plasma from whole blood, the device comprising a conical plastic vessel, the top and bottom of the vessel being open. The lowermost part of the vessel is filled with glass fibres. The blood is then introduced into the free section of the vessel, after which plasma flows through the layer 20 comprising the glass fibres and can be removed at the bottom with the aid of a capillary. US Patent Specification 5,262,067 describes a device for separating plasma from whole blood, in which little haemolysis occurs and in which the device comprises a layer comprising glass fibres coated with polyvinyl alcohol or polyvinyl alcohol/polyvinyl acetate, and a means which causes erythrocytes to aggregate. If an amount of whole blood is applied to the top of the layer, erythrocytes are aggregated and plasma containing little or no haemolysis products passes through the layer. This method and device have, however, the disadvantage that they are unsuitable for expediently separating and isolating plasma from small 30 amounts of whole blood so that said plasma can be used for other diagnostic tests.

The object of the invention is to solve the abovementioned problems and it therefore relates to a method as stated in the preamble, in which a pressure which is lower than the pressure prevailing at ambient temperature prevails in the container. The invention also relates to a kit for separating plasma from whole blood.

Advantages of the method according to the invention are that the method is particularly suitable for separating plasma from small amounts of whole blood, for example amounts of less than 100 µl. Such

amounts can be collected by means of a heel or finger prick in a particularly patient-friendly manner. In addition, such amounts are in many cases quite sufficient for many diagnostic tests, for example tests for determining the concentration of a metabolite, a hormone or an antibody in blood.

For the heel or finger prick, a capillary is advantageously used which comprises a container provided with, for example, a small elliptical needle having a length of less than 1.5 mm.

A further advantage of the invention is that plasmas is 10 obtained from the whole blood in a particularly expedient manner and with a very high yield. Other advantages of the invention are that no special equipment is necessary, so that the separation of plasma from whole blood can be carried out at the site where the patient is. This last advantage may be of particular importance, for example, for doctors who have to treat patients on the spot and in circumstances already described above. A further advantage is that nonspecialists can also separate plasma from whole blood by the method of the invention. In addition, plasma is obtained which only has to be diluted slightly before it is separated from the whole blood. It has been found that a dilution of 100% is 20 adequate, that is to say that the volumetric ratio of plasma to diluent is no higher than 1:5, preferably no higher than 1:3 and in particular no higher than 1:2. According to the method of the present invention, it is possible to obtain only slightly diluted plasma which is very suitable for carrying out diagnostic tests in which a high sensitivity is 25 desirable.

According to the invention, the preparation of the mixture of whole blood, the blood anticoagulant and the diluent is carried out in a hypodermic syringe having a volume of, for example, 1 ml. In this process, the mixture of whole blood and blood anticoagulant is preferably prepared first, after which said mixture is then mixed with the diluent.

According to the invention, the blood anticoagulant is preferably heparin. The diluent may be any buffer solution which is necessary for the desired diagnostic test. An example of such a diluent is a phosphate buffer which contains 0.1% by weight of sodium azide and has a pH of approximately 7.2. The diluent may also contain one or more standard surface-active agents, preferably non-ionic surface-active agents. The diluent may also contain other agents necessary for a particular diagnostic test.

According to the invention, the mixture of whole blood and

WO 97/29369 PCT/NL97/00046

5

blood anticoagulant is preferably prepar d in a capillary which is suitable for collecting a small amount of blood by means of a heel or finger prick and which contains the blood anticoagulant. The mixture of whole blood and blood anticoagulant is then removed with the aid of the 5 hypodermic syringe in which an amount of the diluent has been taken up beforehand. Although it is not preferable according to the invention, it will be clear that it is optionally possible to remove the mixture of whole blood and blood anticoagulant first from the capillary using the hypodermic syringe and then to draw up a certain amount of the diluent 10 with the aid of the hypodermic syringe. According to the invention, it is also preferable that a long and thin hypodermic syringe is used, for example a hypodermic syringe having a length of approximately 7 to approximately 10 cm and a diameter of approximately 3 to approximately 9 mm. Suitable hypodermic syringes are, for example, those which have a volume of 3 ml of the type Sherwood Monoject which are provided with a "Luer lock" (reference No. 1100-503497).

Preferably a hypodermic syringe is used which has been filled with the diluent and an amount of a gas, a pressure below the ambient pressure, preferably a pressure between 1 and 0.5 bar, prevailing in the hypodermic syringe at ambient temperature, which syringe has been provided with a sealing cap. According to the invention, the pressure in the hypodermic syringe at ambient temperature is, in particular, at least 0.5 bar, the hypodermic syringe having a volume of 1 ml and the plunger of the hypodermic syringe being in the fully extended state.

The sealing cap can be pierced by a capillary and is and remains, even after piercing, essentially impermeable to gases. Examples of such sealing caps are septa and ferrules. According to the invention, the sealing caps are preferably made of a material which does not interact with whole blood, the diluent and the gas. The sealing caps are preferably made of an inert plastic material or are coated on the inside with an inert plastic material. A suitable inert plastic material is, for example, Teflon.

25

The hypodermic syringe may be provided with an internal pressure of 0.5 bar by filling it, for example, with a gas having a temperature which is higher than the ambient temperature. After cooling the gas to ambient temperature, a pressure which is lower than the ambient pressure will then be produced in the hypodermic syringe. If the sealing cap is then pricked with the capillary containing the mixture of whole blood and blood anticoagulant, the contents of the capillary will

WO 97/29369 PCT/NL97/00046

be drawn into the hypodermic syringe.

20

25

It will be clear that the hypodermic syringe is filled with a gas which does not interact with the whole blood or a constituent thereof, the blood anticoagulant or the diluent. Examples of suitable 5 gases are nitrogen, oxygen or air.

The mixture containing whole blood, the blood anticoagulant and the diluent is introduced into the hypodermic syringe, whose plunger is already in the completely extended state. To obtain a good mixing, the hypodermic syringe may, if necessary, be rotated horizontally and 10 vertically. The hypodermic syringe may also contain media which promote mixing, for example glass beads, so that mixing can be carried out more expediently. The sealing cap is removed and the hypodermic syringe is then connected to a container which contains the filter comprising glass fibres. The liquid is transferred to the filter by tapping the 15 hypodermic syringe and, after a means of locking the plunger has been broken, preferably by rotating, the contents of the hypodermic syringe are then forced through the filter with the aid of the plunger, a filtrate being obtained in the form of drops which comprises the plasma and contains no haemolysis products.

According to the invention, although partly dependent on the diluent used, drops of plasma are obtained which have a more or less uniform volume. This is achieved by matching the amount and the nature of the surface-active agent used to the properties of the diluent, such as, for example, the pH, the salt concentration and the like.

A great advantage of the method described above is that a kit can be assembled which is suitable for separating a certain amount of plasma which is necessary for the desired diagnostic test. The invention therefore also relates to a kit which comprises at least a container which contains an amount of a diluent necessary for a certain diagnostic 30 test, and a filter containing glass fibres, a pressure prevailing in the container which is lower than the pressure prevailing at ambient temperature. The kit may also contain a capillary which contains an amount of blood anticoagulant necessary for the blood to be collected. The container has a volume which is such that it can contain the amount of whole blood, blood anticoagulant and diluent and, if necessary gas, a pressure of at least 0.5 bar prevailing in the hypodermic syringe at ambient temperature.

According to the invention, it is also possible for the kit as defined hereinabove to comprise a hypodermic syringe which comprises the contain r containing diluent or the diluent alone. Preferably, the kit also contains at 1 ast one diagnostic test which can be carried out with a small amount of plasma, for example with 40 µl of plasma.

Although the blood anticoagulant be contained in the diluent contained in the container may instead of in the capillary, this is generally not to be preferred according to the invention because blood corpuscles may already adhere to the glass wall of the capillary. The kit according to the invention may also contain one or more means necessary for carrying out a certain diagnostic test. Examples of such means are test strips for determining the presence of a certain concentration of metabolite, hormone or antibody in the blood and the reagents necessary therefor.

The invention also relates to a device. A preferred embodiment comprises a hypodermic syringe which is provided with a plunger and means for locking the plunger and which optionally contains media which promote mixing, such as glass beads, a nozzle and a sealing cap for sealing the nozzle, a pressure of at least 0.5 bar prevailing in the hypodermic syringe at ambient temperature. It goes without saying that the hypodermic syringe may be replaced by another suitable container.

The means of locking the plunger have to be present because, if the said means were not present this underpressure would become lower or even be completely eliminated by moving the plunger. The unlocking of the means preferably takes place by means of rotation.

The nozzle of the hypodermic syringe is preferably provided 25 with a common screw thread, for example a "Luer lock" so that the hypodermic syringe can be connected in a simple manner to the container which contains the filter comprising glass fibres. Instead of a screw thread, another means may also be present for connecting the hypodermic syringe to the holder containing the filter.

The nozzle is also provided with a sealing cap. Said sealing cap may partly or in its entirety be composed of a material which can be pierced by a capillary. The material is also essentially impermeable to gases and also remains impermeable to gases if the material has been pierced several times with a capillary. Examples of such materials are plastic materials, preferably elastic inert plastic materials and, in particular, rubber-like materials. Examples of suitable sealing caps are septa and ferrules.

The invention will now be explained by reference to an example.

#### Example 1

An amount of 75 µl of whole blood is collected by a finger prick with the aid of a commercially available capillary containing the standard amount of heparin. This amount of heparin is generally quite sufficient to inhibit the coagulation of the amount of whole blood collected. The whole blood has a haematocrit reading of 0.40 and therefore consists of 45 µl of plasma and 30 µl of blood cells.

An amount of 135 µl of a phosphate buffer having a pH of 7.2 is drawn up with the aid of a hypodermic syringe having a volume of 1 ml.

The mixture of whole blood and heparin is then removed from the capillary with the aid of the hypodermic syringe and the plunger is pulled out to a volume of 1 ml.

A filter which comprises glass fibres and has a dead volume of 38 µl is then mounted on the nozzle of the hypodermic syringe. The 15 hypodermic syringe, which is now provided with the filter, is rotated several times horizontally and vertically to obtain a good mixing of all the constituents. The mixture is transferred to the filter by lightly tapping the hypodermic syringe. The plunger is then carefully pressed in, and three completely clear, colourless drops each having a volume of approximately 40 µl are obtained as filtrate. The yield of plasma is therefore 85%.

#### Example 2

The test of Example 1 was repeated, with the proviso that a pressure of approximately 0.6 bar prevailed in the hypodermic syringe and, at the same time, the hypodermic syringe was provided with a means for locking the plunger. In this test three completely clear, colourless drops were also obtained which had a total volume of approximately 120 µl.

#### Claims

- 1. Method for s parating plasma from whole blood, in which:
- a) a mixture of whole blood, a blood anticoagulant and a diluent is prepared in a container provided with a sealing cap, and
- b) the mixture obtained under a) is passed through a filter containing glass fibres, characterized in that a pressure which is lower than the pressure prevailing at ambient temperature prevails in the container.
- 2. Method according to Claim 1, characterized in that step a) is carried out in a hypodermic syringe.
  - 3. Method according to Claim 1 or 2, characterized in that the diluent contains a non-ionogenic surface-active agent.
- Method according to one of Claims 1 3, characterized in that, in step a), the mixture of whole blood and blood anticoagulant is
   prepared in a capillary.
  - 5. Method according to one of Claims 1 4, characterized in that step a) is carried out with a hypodermic syringe which has been filled with the diluent and an amount of a gas which is such that a pressure of at least 0.5 bar prevails in the hypodermic syringe at ambient
- 20 temperature.
  - 6. Method according to Claim 5, characterized in that the hypodermic syringe is filled with nitrogen, oxygen or air.
- 7. Method according to one of Claims 1 6, characterized in that, in step b), the hypodermic syringe is first connected to a container comprising the filter before the mixture is passed through the filter.
  - 8. Kit for separating plasma from whole blood which comprises at least a container containing a diluent and a filter containing glass fibres, characterized in that a pressure prevails in the container which is lower than the pressure prevailing at ambient temperature.
- 30 9. Kit according to Claim 8, characterized in that the container comprising diluent is a hypodermic syringe.
  - 10. Kit according to Claim 8 or 9, characterized in that the kit contains a capillary which contains a blood anticoagulant.
- 11. Kit according to Claim 8 or 9, characterized in that the kit contains one or more diagnostic tests.

Inte. mad Application No PCT/NL 97/00046

A. CLASSIFICATION OF SUBJECT MATTER
1PC 6 G01N33/49 B01D39/20

Further documents are listed in the continuation of box C.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 6 G01N B01D

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

C. DOCUM	MENTS CONSIDERED TO BE RELEVANT	
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Υ	BE 849 898 A (RECHERCHE ET INDUSTRIE THARAPEUTIQUES, R.I.T.) 28 June 1977 cited in the application	1
A	see page 2, line 37 - page 5, line 4; figures 1-7	2,3,5-9
Y	EP 0 439 917 A (SANGSTAT MEDICAL CORPORATION) 7 August 1991	1
A	see column 4, line 12 - column 12, line 21; figures 1-4	4,10
Υ	FR 2 335 267 A (SHERWOOD MEDICAL INDUSTRIES INC.) 15 July 1977	1
A	see page 4, line 8 - line 21; figure 1	5,6
A	GB 2 232 599 A (DR JULIE ANDREA SUMMERS) 19 December 1990 see the whole document	2,7-10
	-/	

"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	To later document published after the international fiting date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention.  X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone.  Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  &' document member of the same patent family
Date of the actual completion of the international search	Date of mailing of the international search report
25 April 1997	16.05.97
Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tz. 31 651 epo nl, Fax: (+ 31-70) 340-3016	Bosma, R
Form PCT/ISA/210 (second sheet) (July 1992)	

Form PCT/ISA/210 (second sheet) (July 1992

1

X Patent family members are listed in annex.

# INTERNATIONAL SEARCH REPORT

Int onal Application No PCT/NL 97/00046

	A COUNTY CONTROL TO BE ASSESSED.	PCT/NL 97/88846					
C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT  Category * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.							
Α	US 4 263 922 A (WHITE) 28 April 1981 see column 2, line 55 - column 6, line 14; figures 1-6		4,8-10				
A	EP 0 550 950 A (SANWA KAGAKU KENKYUSHO CO.,LTD.) 14 July 1993 see the whole document		1-10				
			·				
			·				
	•		·				
İ							
			·				
ĺ							
l							
			·				
	·						

1

## INTERNATIONAL SEARCH REPORT

information on patent family members

Inte mal Application No PCT/NL 97/00046

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
BE 849898 A	28-06-77	NONE	
EP 439917 A	θ7- <b>08-9</b> 1	AT 133260 T CA 2031073 A DE 69024936 D DE 69024936 T ES 2084670 T JP 3233360 A US 5362654 A US 5147780 A US 5288648 A	15-02-96 02-06-91 29-02-96 14-08-96 16-05-96 17-10-91 08-11-94 15-09-92 22-02-94
FR 2335267 A	15-07-77	US 4180465 A AU 1536476 A BE 846945 A BR 7605513 A CA 1066680 A DE 2635784 A GB 1553596 A	25-12-79 05-01-78 31-01-77 14-03-78 20-11-79 07-07-77 26-09-79
GB 2232599 A	19-12-90	NONE	
US 4263922 A	28-04-81	US 4393882 A	19-07-83
EP 550950 A	14-07-93	JP 5188053 A US 5364533 A	27-07-93 15-11-94